These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30002126)

  • 1. N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.
    Lai JD; Swystun LL; Cartier D; Nesbitt K; Zhang C; Hough C; Dennis JW; Lillicrap D
    Haematologica; 2018 Nov; 103(11):1925-1936. PubMed ID: 30002126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
    Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
    Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
    Arthur CM; Zerra PE; Shin S; Wang J; Song X; Doering CB; Lollar P; Meeks S; Stowell SR
    Blood; 2022 Mar; 139(9):1312-1317. PubMed ID: 34019619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice.
    Peng A; Gaitonde P; Kosloski MP; Miclea RD; Varma P; Balu-Iyer SV
    J Pharm Sci; 2009 Dec; 98(12):4480-4. PubMed ID: 19499565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.
    Gangadharan B; Ing M; Delignat S; Peyron I; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
    Haematologica; 2017 Feb; 102(2):271-281. PubMed ID: 27758819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
    Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
    Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.
    Kannicht C; Ramström M; Kohla G; Tiemeyer M; Casademunt E; Walter O; Sandberg H
    Thromb Res; 2013 Jan; 131(1):78-88. PubMed ID: 23058466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of Mannose-Ending Glycan at Asn
    Delignat S; Rayes J; Dasgupta S; Gangadharan B; Denis CV; Christophe OD; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Front Immunol; 2020; 11():393. PubMed ID: 32273875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of single-site N-linked glycans on factor VIII alters binding of domain-specific monoclonal antibodies.
    Ito J; Baldwin WH; Cox C; Healey JF; Parker ET; Legan ER; Li R; Gill S; Batsuli G
    J Thromb Haemost; 2022 Mar; 20(3):574-588. PubMed ID: 34863021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms.
    Georgescu MT; Moorehead PC; van Velzen AS; Nesbitt K; Reipert BM; Steinitz KN; Schuster M; Hough C; Lillicrap D
    Haematologica; 2018 Aug; 103(8):1403-1413. PubMed ID: 29674503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.
    Reipert BM; Ahmad RU; Turecek PL; Schwarz HP
    Thromb Haemost; 2000 Nov; 84(5):826-32. PubMed ID: 11127864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.
    Purohit VS; Middaugh CR; Balasubramanian SV
    J Pharm Sci; 2006 Feb; 95(2):358-71. PubMed ID: 16372314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
    Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
    Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.
    O'Sullivan JM; Jenkins PV; Rawley O; Gegenbauer K; Chion A; Lavin M; Byrne B; O'Kennedy R; Preston RJ; Brophy TM; O'Donnell JS
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):855-63. PubMed ID: 27013611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
    Oldenburg J; Lacroix-Desmazes S; Lillicrap D
    Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.